涉嫌内幕交易等被立案，董事长姜伟连夜发全员信：恳请员工“坚守岗位”

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. announced that its actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission (CSRC) for insider trading and violations of information disclosure regulations, which is unrelated to the company's daily operations and will not affect its business activities [1][3]. Group 1: Investigation and Company Response - Jiang Wei, who is also the chairman of Guizhou BaiLing, will cooperate with the CSRC during the investigation and has communicated with employees to maintain focus on their work [2][4]. - The company reassured stakeholders that the investigation pertains solely to Jiang Wei and does not impact the company's operations [1]. Group 2: Financial and Legal Context - Jiang Wei is involved in a legal dispute with Huachuang Securities, with a total claim amounting to 1.761 billion yuan, including principal and related fees [6]. - Since 2018, Jiang Wei has faced financial difficulties due to heavy debt burdens and declining stock prices, leading to a significant increase in stock pledge ratios [6][7]. - As of the third quarter, Jiang Wei holds 245.346 million shares, representing 17.55% of the company, all of which are pledged [13][14]. Group 3: Company Performance - Guizhou BaiLing reported a third-quarter revenue of 640 million yuan, a year-on-year increase of 1.11%, while the net profit attributable to shareholders was 4.9798 million yuan, up 559.90% [17]. - For the first three quarters, the company’s revenue was 2.102 billion yuan, a year-on-year decrease of 24.28%, with a net profit of 56.8144 million yuan, down 35.60% [17]. - The company's stock price closed at 5.57 yuan on December 3, reflecting a year-to-date increase of over 44% [17].